Epoch Investment Partners Inc. Grows Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Epoch Investment Partners Inc. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 59.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 85,691 shares of the specialty pharmaceutical company's stock after acquiring an additional 31,957 shares during the period. Epoch Investment Partners Inc. owned 0.16% of Supernus Pharmaceuticals worth $3,099,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC grew its holdings in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after buying an additional 74,438 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after buying an additional 2,121 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $1,498,000. Finally, Smartleaf Asset Management LLC grew its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 870 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of SUPN traded up $0.87 during mid-day trading on Friday, reaching $32.22. 356,067 shares of the company's stock traded hands, compared to its average volume of 495,353. The stock's 50-day moving average is $31.94 and its two-hundred day moving average is $34.97. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a market cap of $1.80 billion, a P/E ratio of 30.11 and a beta of 0.90.

Wall Street Analyst Weigh In

SUPN has been the topic of a number of recent research reports. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 in the last 90 days. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.